Tirzepatide
Tirzepatide is a first-in-class dual GLP-1 and GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It produces greater blood sugar reduction and weight loss than GLP-1 agonists alone. It is injected once weekly.
Uses & FDA Indications
Tirzepatide carries two FDA-approved indications under two separate brand names. Mounjaro was approved in 2022 for the treatment of type 2 diabetes mellitus in adults, as an adjunct to diet and exercise. Zepbound was approved in 2023 for chronic weight management in adults with a body mass index (BMI) of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, or dyslipidemia).
Cardiovascular outcome data for tirzepatide are actively being studied. The SURPASS-CVOT trial is evaluating cardiovascular events in patients with type 2 diabetes and high cardiovascular risk — results are anticipated and will significantly influence prescribing in at-risk populations. Tirzepatide does not replace insulin therapy in type 1 diabetes and is not approved for that indication.
How It Works
Tirzepatide is the first approved dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a synthetic peptide that mimics both incretin hormones simultaneously, which distinguishes it from GLP-1-only agents such as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda).
GLP-1 receptor activation stimulates insulin secretion in a glucose-dependent manner (reducing hypoglycemia risk), suppresses glucagon, slows gastric emptying, and reduces appetite via central nervous system effects. GIP receptor activation complements GLP-1 signaling — GIP stimulates insulin and glucagon secretion, promotes fat metabolism, and may enhance the weight-loss effect of GLP-1 signaling through GIP receptor activity in adipose tissue. The dual mechanism is believed responsible for tirzepatide's superior efficacy compared to GLP-1-only agents in head-to-head trials.
In SURPASS-2, tirzepatide demonstrated greater A1C reduction and greater weight loss than semaglutide 1 mg weekly at all doses studied. In SURMOUNT-1, participants with obesity (without diabetes) lost approximately 22% of body weight on average over 72 weeks — among the largest weight reductions documented in a pharmacological trial for obesity.
FDA BLACK BOX WARNING — THYROID C-CELL TUMORS: Tirzepatide caused dose-dependent thyroid C-cell tumors in rodent studies. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Tirzepatide is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Counsel patients about the potential risk and symptoms of thyroid tumors.
Side Effects
Common — Gastrointestinal
- Nausea — the most common adverse effect; typically most pronounced during titration and improves over time.
- Vomiting — less common than nausea; if persistent, may require dose adjustment or temporary reduction.
- Diarrhea — can occur particularly during dose escalation.
- Constipation — delayed gastric emptying can reduce gut motility; counterintuitively common despite other GI effects.
- Decreased appetite — a therapeutic effect for obesity but can become problematic if intake is severely restricted.
Other Common
- Injection site reactions — redness, bruising, swelling at the injection site; rotating sites reduces this.
- Fatigue — particularly early in treatment.
Serious
- Pancreatitis — GLP-1 class warning; symptoms include severe abdominal pain radiating to the back. Discontinue and do not restart if pancreatitis is confirmed.
- Diabetic retinopathy complications — rapid A1C improvement has been associated with worsening retinopathy in diabetic patients; ophthalmological monitoring is recommended.
- Hypoglycemia — primarily a risk when combined with insulin or sulfonylureas; rare with tirzepatide alone in type 2 diabetes.
- Acute kidney injury — dehydration from severe GI side effects can impair renal function; maintain hydration.
- Thyroid tumors — see black box warning above.
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Insulin | Additive glucose-lowering effect significantly increases hypoglycemia risk when tirzepatide is combined with insulin. | High — insulin dose reduction is typically required; monitor blood glucose closely when initiating tirzepatide |
| Sulfonylureas (glipizide, glimepiride, glyburide) | Additive insulin secretagogue effect raises hypoglycemia risk. | Moderate-High — consider reducing sulfonylurea dose when starting tirzepatide |
| Oral contraceptives | Tirzepatide slows gastric emptying, which may delay absorption of oral medications. Oral hormonal contraceptives may be affected; alternative or backup contraception is recommended during treatment. | Moderate — consider non-oral contraceptive methods; discuss with prescriber |
| Warfarin | Delayed gastric emptying and metabolic changes may affect warfarin absorption and metabolism. INR can fluctuate when tirzepatide is initiated or titrated. | Moderate — monitor INR frequently when initiating or changing tirzepatide |
| Other oral medications with narrow therapeutic windows | Delayed gastric emptying can alter the absorption timing and peak levels of oral drugs that depend on rapid or time-sensitive absorption. | Variable — assess individual drugs; consider whether timing of administration relative to tirzepatide injection matters |
Warnings & Contraindications
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Hypersensitivity to tirzepatide
- Type 1 diabetes mellitus (not approved; insulin replacement is required)
Pancreatitis
GLP-1 receptor agonists as a class carry a warning regarding acute pancreatitis, including fatal and non-fatal cases. Evaluate patients for pancreatitis at the onset of severe abdominal pain. If pancreatitis is confirmed, do not restart tirzepatide. Exercise caution in patients with a history of pancreatitis, though this is not an absolute contraindication.
Pregnancy
Tirzepatide should be discontinued before a planned pregnancy. Based on animal data, it may cause fetal harm. Women of childbearing potential who are using tirzepatide for weight management should use effective contraception. Because tirzepatide may alter oral contraceptive absorption, an alternative contraceptive method should be discussed with the prescriber.
Check for hypoglycemia risk or other interactions involving tirzepatide.
Check Drug Interactions →Frequently Asked Questions
Is Mounjaro better than Ozempic?
Head-to-head trial data — specifically the SURPASS-2 trial — showed tirzepatide (Mounjaro) achieved greater A1C reduction and greater weight loss than semaglutide (Ozempic) in adults with type 2 diabetes. The likely explanation is tirzepatide's dual mechanism: it activates both GIP and GLP-1 receptors, while semaglutide activates GLP-1 receptors only. In terms of weight loss specifically, SURMOUNT-1 showed approximately 22% mean body weight reduction with tirzepatide, which compares favorably with the approximately 15% seen in semaglutide's STEP trials. Both are highly effective; individual patient factors, tolerability, cost, and access all influence the choice.
What is the difference between Mounjaro and Zepbound?
Mounjaro and Zepbound are the same drug — tirzepatide — marketed under different brand names for different FDA-approved indications. Mounjaro was approved first, for type 2 diabetes management. Zepbound was subsequently approved for chronic weight management in adults with obesity or overweight with a weight-related comorbidity. The active ingredient, formulation, and delivery device are identical. The distinction exists primarily for regulatory, insurance reimbursement, and marketing purposes.
How much weight can you lose on tirzepatide?
Clinical trial data from the SURMOUNT-1 study showed participants lost approximately 22% of body weight on average over 72 weeks with the highest dose of tirzepatide. About 91% of participants achieved at least 5% weight loss, and approximately 57% achieved at least 20% weight loss. These results are among the largest weight reductions seen in any pharmacological trial for obesity to date. Real-world results vary based on adherence, diet, activity, and individual physiology. Weight tends to return when tirzepatide is discontinued, underscoring that obesity is a chronic condition requiring ongoing management.